Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window

This article was originally published in The Tan Sheet

Executive Summary

The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit

You may also be interested in...

Declaratory Orders For Drug Firms Could Come Easier With High Court Ruling

The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could come in a case brought by Teva against Novartis regarding Famvir

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts